Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mTOR”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06437574
What this trial is testing

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Who this might be right for
Prostate Cancer
Cedars-Sinai Medical Center 140
Large-scale testing (Phase 3)UnknownNCT03987152
What this trial is testing

Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life

Who this might be right for
Vascular Malformations
Radboud University Medical Center 75
Post-approval studies (Phase 4)Study completedNCT02328963
What this trial is testing

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Who this might be right for
Transplantation InfectionCytomegalovirus Infection
University Hospital, Bordeaux 186
Not applicableStudy completedNCT01649609
What this trial is testing

Using mTOR Inhibitors in the Prevention of BK Nephropathy

Who this might be right for
BK ViremiaBK Nephropathy
Columbia University 40
Very early researchLooking for participantsNCT06658093
What this trial is testing

RESTOR: PK/PD mTORi Inhibition in Older Adults

Who this might be right for
Aging
The University of Texas Health Science Center at San Antonio 194
Large-scale testing (Phase 3)Study completedNCT01707849
What this trial is testing

The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

Who this might be right for
Hepatitis C Recurrence After Liver Transplant
Hospital Vall d'Hebron 18
Testing effectiveness (Phase 2)Study completedNCT03383380
What this trial is testing

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

Who this might be right for
Activated PI3K-delta SyndromeImmunodeficiency Primary
Children's Hospital of Fudan University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06301386
What this trial is testing

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Who this might be right for
Colon Cancer
Fudan University 25
Post-approval studies (Phase 4)UnknownNCT06584773
What this trial is testing

Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients

Who this might be right for
Disorder Related to Renal Transplantation
University of Sao Paulo General Hospital 80
Testing effectiveness (Phase 2)Study completedNCT01526356
What this trial is testing

Topical Rapamycin to Erase Angiofibromas in TSC

Who this might be right for
AngiofibromasTuberous Sclerosis
The University of Texas Health Science Center, Houston 179
Testing effectiveness (Phase 2)Study completedNCT00519324
What this trial is testing

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Who this might be right for
Advanced Gastric Cancer
Novartis Pharmaceuticals 54
Testing effectiveness (Phase 2)Ended earlyNCT01637090
What this trial is testing

Everolimus in Treating Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-Cell Lymphoma
Adam Lerner 3
Testing effectiveness (Phase 2)Study completedNCT01520103
What this trial is testing

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Who this might be right for
Her2-negative Metastatic Breast CancerHer2-negative Locally Advanced Breast Cancer
AIO-Studien-gGmbH 139
Large-scale testing (Phase 3)UnknownNCT05954442
What this trial is testing

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Who this might be right for
Triple Negative Breast CancerMetastatic Breast CancerMutation
Fudan University 203
Testing effectiveness (Phase 2)Study completedNCT02216786
What this trial is testing

Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Who this might be right for
Estrogen Receptor Positive Breast Cancer
Queen Mary University of London 333
Early research (Phase 1)Study completedNCT03730142
What this trial is testing

WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Advanced Cancer
Shanghai Jiatan Pharmatech Co., Ltd 82
Testing effectiveness (Phase 2)UnknownNCT02730923
What this trial is testing

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

Who this might be right for
Endometrial CarcinomaMetastatic CarcinomaHormone Receptor Positive Tumor
Centre Leon Berard 72
Not applicableStudy completedNCT07197151
What this trial is testing

CYFIP1 and PKM2 Synergistically Regulate ROS and Glycolysis in Colorectal Cancer Through the AKT/mTOR/HIF-1α Cascad

Who this might be right for
Colorectal Cancer (CRC)Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
hui hou 32
Early research (Phase 1)Ended earlyNCT01174199
What this trial is testing

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate Cancer+2 more
Roswell Park Cancer Institute 13
Testing effectiveness (Phase 2)UnknownNCT04998760
What this trial is testing

Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )

Who this might be right for
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
Qi Zhou 96
Next Page